医学
放射外科
倾向得分匹配
危险系数
前瞻性队列研究
观察研究
栓塞
冲程(发动机)
队列
颅内动静脉畸形
动静脉畸形
比例危险模型
队列研究
外科
内科学
血管造影
脑血管造影
放射治疗
置信区间
机械工程
工程类
作者
Hengwei Jin,Zhipeng Li,Dezhi Gao,Yú Chen,Heze Han,Li Ma,Debin Yan,Ruinan Li,Anqi Li,Haibin Zhang,Kexin Yuan,Yukun Zhang,Jing Wang,Xiangyu Meng,Youxiang Li,Xiaolin Chen,Hao Wang,Shibin Sun,Yuanli Zhao
标识
DOI:10.1136/jnis-2023-020289
摘要
Background To compare the long-term outcomes of stereotactic radiosurgery (SRS) with or without prior embolization in brain arteriovenous malformations (AVMs) (volume ≤10 mL) for which SRS is indicated. Methods Patients were recruited from a nationwide multicenter prospective collaboration registry (the MATCH study) between August 2011 and August 2021, and categorized into combined embolization and SRS (E+SRS) and SRS alone cohorts. We performed propensity score-matched survival analysis to compare the long-term risk of non-fatal hemorrhagic stroke and death (primary outcomes). The long-term obliteration rate, favorable neurological outcomes, seizure, worsened mRS score, radiation-induced changes, and embolization complications were also evaluated (secondary outcomes). Hazard ratios (HRs) were calculated using Cox proportional hazards models. Results After study exclusions and propensity score matching, 486 patients (243 pairs) were included. The median (IQR) follow-up duration for the primary outcomes was 5.7 (3.1–8.2) years. Overall, E+SRS and SRS alone were similar in preventing long-term non-fatal hemorrhagic stroke and death (0.68 vs 0.45 per 100 patient-years; HR=1.46 (95% CI 0.56 to 3.84)), as well as in facilitating AVM obliteration (10.02 vs 9.48 per 100 patient-years; HR=1.10 (95% CI 0.87 to 1.38)). However, the E+SRS strategy was significantly inferior to the SRS alone strategy in terms of neurological deterioration (worsened mRS score: 16.0% vs 9.1%; HR=2.00 (95% CI 1.18 to 3.38)). Conclusions In this observational prospective cohort study, the combined strategy of E+SRS does not show substantial advantages over SRS alone. The findings do not support pre-SRS embolization for AVMs with a volume ≤10 mL.
科研通智能强力驱动
Strongly Powered by AbleSci AI